The adjustment in price target by BMO Capital, while maintaining an Outperform rating, suggests a positive outlook on AbbVie's performance but with a slightly moderated growth expectation. This could lead to a neutral short-term impact on AbbVie's stock price as the market digests the revised target alongside the continued positive rating.